Abstracts tagged "rheumatoid arthritis (RA) and tocilizumab"

Abstract Number: 1495 • 2016 ACR/ARHP Annual Meeting
Lipoprotein(a) Concentrations in Rheumatoid Arthritis on Biologic Therapy: Results from the Cardiovascular in Rheumatology [CARMA] Study Project
Maria Carmen Garcia-Gomez¹, Maria Auxiliadora Martin², Santos Castañeda³, Fernando Sánchez-Alonso⁴, Miren Uriarte Ecenarro⁵, Carlos González-Juanatey⁶, Romera-Baures Monserrat⁷, Santos-Rey Jose⁸, Jose A Pinto-Tasende⁹, Estefania QuesadaMasachs¹⁰, Jesús Tornero¹¹, Olga Martínez González¹², Tatiana Cobo-Ibáñez¹³, Eugenio Chamizo Carmona¹⁴, Sara Manrique-Arija¹⁵, Dolores Fábregas-Canales¹⁶, Federico Díaz-González¹⁷, Javier Llorca¹⁸, Miguel Angel González-Gay¹⁹ and CARMA Collaborative Group, ¹Rheumatology, Consorci Sanitari de Terrassa, Terrassa (Barcelona), Spain, ²Research Unit of Spanish Society of Rheumatology,, Madrid, Spain, ³Rheumatology, Hospital de la Princesa, IIS-IP, Madrid, Spain, ⁴Research Unit of Spanish Society of Rheumatology, Madrid, Spain, ⁵Donostia University Hospital, San Sebastian, Spain, ⁶Division or Cardiology, Hospital Lusus Augusti, Lugo, Spain, ⁷Rheumatology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat (Barcelona), Spain, ⁸Rheumatology, Hospital Virgen de la Salud, Toledo, Spain, ⁹Rheumatology Division, INIBIC-Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruna, Spain, ¹⁰Rheumatology, Hospital Universitari Vall d’Hebron, Barcelona, Spain, ¹¹Rheumatology Department, Hospital Universitario Guadalajara, Guadalajara, Spain, ¹²Rheumatology, HOSPITAL CLÍNICO UNIVERSITARIO DE SALAMANCA, Salamanca, Spain, ¹³Hospital Universitario Reina Sofía, Universidad Europea de Madrid, Madrid, Spain, ¹⁴Rheumatology, Hospital de Mérida, Mérida, Spain, ¹⁵Rheumatology, Hospital Carlos Haya, Malaga, Spain, ¹⁶Rheumatology, Hospital de Barbastro, Barbastro (Huesca), Spain, ¹⁷Rheumatology, Hospital Universitario de Canarias, S/C Tenerife, Spain, ¹⁸Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, ¹⁹Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain
Background/Purpose: Plasma concentrations of lipoprotein (a) [Lp(a)], a lipoprotein with proatherogenic and thrombogenic properties, have a strong genetic basis, although high concentrations of Lp(a) have…
Abstract Number: 1581 • 2016 ACR/ARHP Annual Meeting
The Combination of IL-6 and IL-6 Receptor Levels As a Biomarker of Response to Tocilizumab in Rheumatoid Arthritis Patients
Cesar Diaz-Torne¹, Maria A. Ortiz², Patricia Moya³, M. Victoria Hernández⁴, Delia Reina⁵, Ivan Castellvi⁶, Juan Jose De Agustin⁷, Diana De La Fuente⁸, Hector Corominas^9,10, Raimon Sanmarti¹¹, Josep Maria De Llobet Zubiaga¹ and Silvia Vidal², ¹Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain, ²Institut de Recerca Sant Pau, Barcelona, Spain, ³Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ⁵Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, ⁶Rheumatology, Hospital de Sant Pau, Barcelona, Spain, ⁷Rheumatology, Hospital Baix de Llobregat, Barcelona, Spain, ⁸Rheumatology, Hospital de Viladecans, Barcelona, Spain, ⁹Rheumatology, Hospital Moises Broggi, Barcelona, Spain, ¹⁰Servei de Reumatologia, Hospital Moises Broggi, Barcelona, Spain, ¹¹Arthritis Unit. Rheumatology, Arthritis Unit. Rheumatology Department. Hospital Clínic, Barcelona, Spain
Background/Purpose: Several predictors of response to tocilizumab have been described. They include a low HAQ, high baseline CRP or NK levels and certain IL-6R polymorphisms.…
Abstract Number: 1592 • 2016 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Parallel-Group, Phase III Study of Shortening the Dosing Interval of Subcutaneous Tocilizumab Monotherapy in RA Patients with an Inadequate Response to Subcutaneous Tocilizumab Every Other Week
Atsushi Ogata¹, Nobuhiro Takagi², Hiroko Miwa³ and the MRA231JP study group, ¹Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine and NTT West Osaka Hospital, Osaka, Japan, ²Chugai Pharmaceutical Co. Ltd., Tokyo, Japan, ³Chugai Pharmaceutical Co. Ltd, Tokyo, Japan
Background/Purpose: The non-inferiority of subcutaneous tocilizumab (TCZ-SC) monotherapy every 2 weeks (q2w) to intravenous TCZ monotherapy every 4 weeks was demonstrated in Japanese patients with…
Abstract Number: 588 • 2015 ACR/ARHP Annual Meeting
Prospective Study about Extension of Dosing Interval with Tocilizumab Therapy in Rheumatoid Arthritis Patients in Remission Maintenance
Jun Kikuchi, Akiko Shibata, Ryota Sakai, Kentaro Chino, Tsuneo Kondo, Ayumi Okuyama, Hirofumi Takei and Koichi Amano, Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
Background/Purpose: Tocilizumab (TCZ) is clinically effective against rheumatoid arthritis (RA) and over 50% of RA patients who had completed 5 years of TCZ treatment maintained…
Abstract Number: 593 • 2015 ACR/ARHP Annual Meeting
Predicting the Need for Additional Treatment in Early Rheumatoid Arthritis Patients Treated to Target on Methotrexate Monotherapy
Xavier Teitsma¹, Johannes Jacobs², Paco Welsing³, Thasia Woodworth⁴, Attila Pethö-Schramm⁵, Michelle Borm⁶, Corrado Bernasconi⁵, Floris Lafeber¹ and Johannes W J Bijlsma⁷, ¹Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Department Rheumatology and clinical immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Medicine, Division of Rheumatology, David Geffen School of Medicine, Los Angeles, CA, ⁵F. Hoffmann-La Roche, Basel, Switzerland, ⁶Beneluxlaan 2a, Roche Nederland BV, Woerden, Netherlands, ⁷Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Joint damage and functional disability can be reduced by intensive treatment of newly diagnosed rheumatoid arthritis (RA) patients during the "window of opportunity". Although…
Abstract Number: 600 • 2015 ACR/ARHP Annual Meeting
Tocilizumab Serum Trough Levels and Disease Activity in Rheumatoid Arthritis
Virginia Ruiz-Esquide¹, Pascal Zufferey², Jose Inciarte-Mundo¹, Jordi Yagüe³, M. Victoria Hernández⁴, Julio Ramirez¹, Jeanne Berner², Mariona Pascal³, Andrea Cuervo¹, Juan D. Cañete⁵ and Raimon Sanmarti^1,6, ¹Arthritis Unit. Rheumatology, Hospital Clínic of Barcelona, Barcelona, Spain, ²Rheumatology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, ³Immunology, Hospital Clínic of Barcelona, Barcelona, Spain, ⁴Hospital Clínic i Provincial, Barcelona, Spain, ⁵Arthritis Unit, Rheumatology, Hospital Clínic of Barcelona, Barcelona, Spain, ⁶Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain
Background/Purpose: Tocilizumab (TCZ) is a humanized anti-IL-6R monoclonal antibody approved for the treatment of active rheumatoid arthritis (RA) (EMA: 8mg/kg q4w). Response to treatment may…
Abstract Number: 613 • 2015 ACR/ARHP Annual Meeting
Correlation Between Efficacy of Tocilizumab and Levels of Oxidative Stress Markers in Patients with Rheumatoid Arthritis: the 52-Week Analysis
Hiroaki Niiro¹, Hiroshi Tsukamoto², Yojiro Arinobu², Mitsuteru Akahoshi², Hiroki Mitoma², Kensuke Oryoji³, Yasushi Inoue⁴, Takuya Sawabe⁵, Shuji Nagano⁶, Hiroaki Nishizaka⁷, Seiji Yoshizawa⁸, Yoshifumi Tada⁹, Shigeru Yoshizawa¹⁰, Takeshi Otsuka¹¹, Akira Ueda¹², Hitoshi Nakashima¹³, Takahiko Horiuchi¹⁴ and Koichi Akashi², ¹Clinical Education Center, Kyushu University Hospital, Fukuoka, Japan, ²Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan, ³The Center for Rheumatic Diseases, Matsuyama Red Cross Hospital, Matsuyama, Japan, ⁴Department of Rheumatology, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan, ⁵Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima, Japan, ⁶Kyushu multicenter rheumatoid arthritis ultrasound prospective observational cohort study group, Nagasaki, Japan, ⁷Kitakyushu Municipal Medical Center, Kitakyushu, Japan, ⁸Hamanomachi Hospital, Fukuoka, Japan, ⁹Department of Internal Medicine, Division of Rheumatology, Saga University, Saga, Japan, ¹⁰Department of Rheumatology, Fukuoka Hospital, National Hospital Organization, Fukuoka, Japan, ¹¹Munakata Medical Association Hospital, Munakata, Japan, ¹²Department of Internal Medicine, Miyazaki Prefectural Hospital, Miyazaki, Japan, ¹³Div of Nephrol & Rheumatol, Dept of Int Med, Faculty of Medicine, Fukuoka University, Fukuoka, Japan, ¹⁴Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan
Background/Purpose: Despite their profound inhibitory effects on inflammation and bone destruction, it remains unclear whether biological therapies can improve the long-term prognosis of patients with…
Abstract Number: 1602 • 2015 ACR/ARHP Annual Meeting
Beta Cells Function and Insulin Resistance during Tocilizumab Treatment in Non-Diabetic RA Patients: Results from a Single-Center Study
Gorica Ristic¹, Vesna Subota², Petar Ristic³, Dejana Stanisavljevic⁴, Arsen Ristic⁵, Branislava Glisic¹, Milan Petronijevic¹ and Dusan Stefanovic¹, ¹Department of Rheumatology and Clinical Immunology, Military Medical Academy, Belgrade, Serbia, ²Institute of Medical Biochemistry, Military Medical Academy, Belgrade, Serbia, ³Department of Endocrinology, Military Medical Academy, Belgrade, Serbia, ⁴Institute of Medical Statistics, Belgrade University School of Medicine, Belgrade, Serbia, ⁵Department of Cardiology, Clinical Center of Serbia & Belgrade University School of Medicine, Belgrade, Serbia
Background/Purpose: Insulin resistance (IR) is increased and β-cell function impaired in rheumatoid arthritis (RA). The aim of this study was to evaluate whether treatment with…
Abstract Number: 1651 • 2015 ACR/ARHP Annual Meeting
Comparison of Oral Glucocorticoid (OGC)-Sparing Effects in Tocilizumab and Other Biologic Dmards Using Multilevel Models in an Administrative Health Care Claims Database
Brandon Arnieri¹, Khaled Sarsour¹, David Oliveri¹, Attila Pethö-Schramm², Avani Shah¹ and George Quartey¹, ¹Genentech, South San Francisco, CA, ²F. Hoffmann-La Roche, Basel, Switzerland
Background/Purpose : The current treatment paradigm in rheumatoid arthritis (RA) is to attempt to decrease, when clinically feasible, concomitant use of OGCs after their use…
Abstract Number: 1664 • 2015 ACR/ARHP Annual Meeting
Switch from Tocilizumab + Methotrexate to Tocilizumab Monotherapy. Maintenance of Response in Patients with Rheumatoid Arthritis at Low Disease Activity.
Jose L. Pablos¹, Navarro Sarabia F², Francisco J. Blanco³, Jose Andres Roman Ivorra⁴, Alberto Alonso⁵, Emilio Martin-Mola⁶ and Miguel Cantalejo-Moreira⁷, ¹Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain, ²Rheumatologist Service, Hospital. Virgen Macarena, Sevilla, Spain, ³Cartilage Biology Group. Rheumatology Division, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ⁴Rheumatology, H.U. P. La Fe, Valencia, Spain, ⁵H Cruces, Baracaldo, Spain, ⁶H La Paz, Madrid, Spain, ⁷Rheumatology Unit, Hospital de Fuenlabrada, Fuenlabrada, Spain
Background/Purpose: Tocilizumab (TCZ) represents an efficacious alternative for patients with rheumatoid arthritis (RA) with an inadequate clinical response to biological or non-biological disease-modifying anrirheumatic drugs…
Abstract Number: 2731 • 2015 ACR/ARHP Annual Meeting
Persistency of Tocilizumab As Monotherapy or Combination Therapy in Patients with Rheumatoid Arthritis–Real-World Analyses from the US Corrona Registry
Dimitrios A. Pappas^1,2, Ani John³, Carol J. Etzel^2,4, Chitra Karki², YouFu Li⁵, Joel M. Kremer⁶, Tmirah Haselkorn³ and Jeffrey D. Greenberg^2,7, ¹Columbia University, New York, NY, ²Corrona, LLC, Southborough, MA, ³Genentech, Inc, South San Francisco, CA, ⁴The University of Texas MD Anderson Cancer Center, Houston, TX, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶Albany Medical College and The Center for Rheumatology, Albany, NY, ⁷NYU School of Medicine, New York, NY
Background/Purpose: For patients with rheumatoid arthritis (RA), there are limited real-world data on factors that predict persistency on biologic therapy or whether use of biologics…
Abstract Number: 2753 • 2015 ACR/ARHP Annual Meeting
Effectiveness and Safety of Tocilizumab in Biologics-Naive RA Patients – Postmarketing Surveillance for Investigating Success in Achieving Clinical and Functional Remission and Sustaining Efficacy with Tocilizumab in Biologics-Naive RA Patients (FIRST Bio) Study
Naoki Ishiguro¹, Tatsuya Atsumi², Masayoshi Harigai³, Tsuneyo Mimori⁴, Norihiro Nishimoto⁵, Takayuki Sumida⁶, Tsutomu Takeuchi⁷, Yoshiya Tanaka⁸, Nobuhiro Takagi⁹, Ayako Nakasone¹⁰ and Hisashi Yamanaka¹¹, ¹Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan, ²Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ³Department of Phamacovigilance, Tokyo Medical and Dental University, Tokyo, Japan, ⁴Dept of Rheum & Clinical Immun, Kyoto Univ Grad Schl of Med, Kyoto, Japan, ⁵Osaka Rheumatology Clinic, Osaka, Japan, ⁶Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ⁷Keio University School of Medicine, Tokyo, Japan, ⁸The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁹Medical Science, Chugai Pharmaceutical, Tokyo, Japan, ¹⁰Chugai Pharmaceutical Co. Ltd, Tokyo, Japan, ¹¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: The all-patient postmarketing surveillance (PMS) of tocilizumab (TCZ; PMS7901), which followed 7901 rheumatoid arthritis (RA) patients for 28 weeks (wks), showed that patients with…
Abstract Number: 2756 • 2015 ACR/ARHP Annual Meeting
Impact of Tocilizumab Monotherapy on Patient-Reported Quality of Life Outcomes in the US Corrona Registry
Leslie Harrold^1,2, Ani John³, George W. Reed^2,4, Chitra Karki², YouFu Li⁴, Joel M. Kremer⁵, Tmirah Haselkorn⁶ and Jeffrey D. Greenberg^2,7, ¹Department of Orthopedics and Medicine, University of Massachusetts Medical School, Worcester, MA, ²Corrona, LLC, Southborough, MA, ³Genentech, Inc., South San Francisco, CA, ⁴University of Massachusetts Medical School, Worcester, MA, ⁵Albany Medical College, Albany, NY, ⁶Genentech, Inc, South San Francisco, CA, ⁷NYU School of Medicine, New York, NY
Background/Purpose: The objective of this real-world analysis was to examine the impact of the interleukin-6 receptor α inhibitor tocilizumab (TCZ) on patient-reported outcomes (PROs) in…
Abstract Number: 2771 • 2015 ACR/ARHP Annual Meeting
Impact of Tocilizumab Monotherapy in Patients with Moderate to High Disease Activity: Real-World Analyses from the US Corrona Registry
Leslie Harrold^1,2, Ani John³, George W. Reed^1,4, Chitra Karki¹, YouFu Li⁴, Joel Kremer⁵, Tmirah Haselkorn⁶ and Jeffrey D. Greenberg^1,7, ¹Corrona, LLC, Southborough, MA, ²Department of Orthopedics and Medicine, University of Massachusetts Medical School, Worcester, MA, ³Genentech, Inc., South San Francisco, CA, ⁴University of Massachusetts Medical School, Worcester, MA, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY, ⁶Genentech, Inc, South San Francisco, CA, ⁷NYU School of Medicine, New York, NY
Background/Purpose: Little is known regarding the real-world use and effectiveness of the interleukin-6 receptor α inhibitor tocilizumab (TCZ) as monotherapy. The effectiveness of TCZ monotherapy…
Abstract Number: 2782 • 2015 ACR/ARHP Annual Meeting
Not Only 5 but Also 6 Weeks Intervals of Tocilizumab Infusion Induce Clinical Remission in Patients with Active Rheumatoid Arthritis
Hiroshi Uda¹, Koji Shigematsu², Yoshitaka Ishizaki² and Osamu Saiki^1,3, ¹Rheumatology, Higashiosaka City General Hospital, Higashiosaka, Japan, ²Orthopedics, Higashiosaka City General Hospital, Higashiosaka, Japan, ³Rheumatology, Shiraishi Hospital, Imabari, Japan
Background/Purpose: For active rheumatoid arthritis patients with inadequate response to synthetic disease modifying antirheumatic drugs (DMARDs), biologic agents are indicated. However, the cost of biologics,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].